Abuse, dependence, and epileptic seizures after zolpidem withdrawal: Review and case report

被引:47
作者
Aragona, M [1 ]
机构
[1] Univ La Sapienza, Psychiat Clin 1, I-00185 Rome, Italy
关键词
insomnia; anxiety; abuse; dependence; withdrawal; seizures; epilepsy; convulsions; side effects;
D O I
10.1097/00002826-200009000-00008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The imidazopyridine zolpidem is a short-acting hypnotic chemically distinct from benzodiazepines (BZs). According to its peculiar neuropharmacologic activity (selectivity for the omega 1-BZ receptors), zolpidem is expected to be a pure hypnotic, without the other effects of BZs. In particular, it has been stressed that zolpidem is well tolerated in adults and in the elderly, and that tolerance, abuse, dependence, rebound insomnia, and other withdrawal effects do not develop in relation to zolpidem administration. However, despite these assumptions, zolpidem abuse, dependence, and withdrawal effects have been recently discussed and reviewed herein. In addition, the case of a 43-year-old woman who had an epileptic attack after abrupt interruption of an abused, high dose of zolpidem (600 mg/d), is reported and discussed. At the clinical level, it is stressed that the subjective effects of zolpidem are comparable to those of other BZs, and that abuse, dependence, and withdrawal seizures cannot be avoided simply shifting the regimen of a BZ abuser to zolpidem. At the pharmacologic level, it is important to note that zolpidem's clinical effects cannot be explained on the basis of the old distinction between omega 1 and 2 receptors because this distinction is no longer valid; the new classification of GABA(A) receptor subtypes is reported and zolpidem activity at this level is discussed herein.
引用
收藏
页码:281 / 283
页数:3
相关论文
共 20 条
  • [1] General safety profile of zolpidem: Safety in elderly, overdose and rebound effects
    Allain, H
    Monti, J
    [J]. EUROPEAN PSYCHIATRY, 1997, 12 : S21 - S29
  • [2] Barnard EA, 1998, PHARMACOL REV, V50, P291
  • [3] RESULTS OF A MULTICENTER TRIAL WITH THE HYPNOTIC ZOLPIDEM IN 1152 INSOMNIAC PATIENTS
    BIONDI, F
    CASADEI, GL
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1994, 55 (03): : 262 - 274
  • [4] The safety and tolerability of zolpidem -: an update
    Darcourt, G
    Pringuey, D
    Sallière, D
    Lavoisy, J
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 1999, 13 (01) : 81 - 93
  • [5] Seizure after withdrawal from supratherapeutic doses of zolpidem tartrate, a selective omega I benzodiazepine receptor agonist
    Gilbert, DL
    Staats, PS
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 14 (02) : 118 - 120
  • [6] Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases
    Hajak, G
    Bandelow, B
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (04) : 157 - 167
  • [7] KAPLAN HI, 1997, KAPLAN SADOCKS SYNOP
  • [8] Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal
    Monti, JM
    Monti, D
    Estevez, F
    Giusti, M
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 (04) : 255 - 263
  • [9] COMPARISON OF THE EFFICACY AND TOLERABILITY OF ZOLPIDEM 20 MG AND TRIAZOLAM 0.5 MG IN ANXIOUS OR DEPRESSED INSOMNIAC PATIENTS
    PAGOT, R
    CRAMER, P
    LHERITIER, C
    COQUELIN, JP
    ATTALI, P
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 53 (01): : 88 - 97
  • [10] Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
    Rudolph, U
    Crestani, F
    Benke, D
    Brünig, I
    Benson, JA
    Fritschy, JM
    Martin, JR
    Bluethmann, H
    Möhler, H
    [J]. NATURE, 1999, 401 (6755) : 796 - 800